

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

(Set up under the Department of Pharmaceuticals, Government of India)



Order

Tender No. BPPI/Drug- 050/2017 dated 25.05.2017

Dated:25/02/2020

To,

M/s Kwality Pharmaceuticals Ltd. 6th Milestone, Village Nag Kalan, Majitha Road, Amritsar 143601, Punjab India.

Whereas, Bureau of Pharma Public Sector Undertakings of India, New Delhi had published tender no. BPPI/Drugs-050/2017 dated 25/05/2017 through e-procurement system i,e CPP Portal for supply of drugs for the year 2017-2019.

Whereas, M/s Kwality Pharmaceuticals Ltd.6th Milestone, Village Nag Kalan, Majitha Road, Amritsar- 143601, Punjab India. had participated in the tender. The firm was awarded Drug Code-212, Pantoprazole Enteric coated Tablet IP 40 mg. & supplied to BPPI, New Delhi for the period of 2 years as per tender provision. Samples of Drug code 212 Pantoprazole Enteric coated Tablet IP 40 mg. having batch no. T-6278, T-6708, T-7224 & T-7227 was found NOT OF STANDARD QUALITY after testing in Government laboratory as per details below:

Product Name	Batch No.	Mfg. date	Exp. Date	Reason of rejection	Failed by	Report no.	Show cause by BPPI
Pantoprazole Enteric coted tablets IP 40 mg	T-6278	Jan.2018	Dec.2019	The Sample Fails in Dissolution test	Government Analyst, RDT, Guwahati & DI, Naharlagun, A.P	RDTL/2130/2018- 19 Dated 13.03.2019	31.07.2019 (Tender no.50)
Pantoprazole Enteric coted tablets IP 40 mg	T-6708	May.2018	Apr.2020	The Sample Fails in Dissolution test	Government Analyst, Karnataka	1110-HUB-18- 19/W-2-1718 dated: 30/04/2019	14.08.2019 (Tender no.50)
Pantoprazole Enteric coted tablets IP 40 mg	T-7224	Nov.2018	Oct-2020	The Sample Fails in Dissolution test	Government Analyst, Regional Drugs Testing Laboratory &DI Naharlagun, A.P	RDTL/3268/2019- 20 dated 05/11/2019	30.12.2019 (Tender no.50)
Pantoprazole Enteric coted tablets IP 40 mg	T-7227	Nov.2018	Oct.2020	The Sample Fails in Dissolution test	DI Shopian J&K	L/DA/2019- 20/1104 dated 18/12/2019	27.01.2020 (Tender no.50)

Whereas, Bureau of Pharma Public Sector Undertakings of India, New Delhi issued Show cause notice to the firm informing about provisions of the clause no. 15.2, 19.2 & 20.1(a) of tender document with request to explain within 7 days why not following actions against them may be taken: -

- (i) Recovery of NSQ batches amount as per clause 15.2 and 19.2, of tender document.
- (ii) blacklisting/debarring of the firm as per clause 19.2 and 20.1(a) of tender document.

Page 1 of 2



BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

(Set up under the Department of Pharmaceuticals, Government of India)



Whereas, The firm vide their letter for B.No.-T-6278 dated 23.04.2019, B.No.-T-6708 dated 05.06.2019, B.No.-T-7224 dated 05.01.2020 & B.No.-T-7227 dated 08.02.2020 informed that they had challenged the NSQ drug foe re-testing in CDL, Kolkata and also informed that the problem arises as product is sensitive to heat, Light and moisture. But BPPI has not received any letter/test report from any drug department and CDL. The Explanation of the firm is not acceptable as the reports received from the Government Drug Testing Laboratory will be conclusive, final and binding on the suppliers in terms of provision of clause 20.2.2 of tender document.

In view of above, the **firm** is debarred for a period of 2 years to participate in any tender of BPPI for supplying of drug i.e. **Drug code 212 Pantoprazole Enteric coated Tablet IP 40 mg** from date of issuance of this order and liable for recovery of total cost of NSQ batches.

This order is without prejudice to the legal and criminal action to be taken if any, by Bureau of Pharma Public Sector Undertakings of India, New Delhi in the matter.

Sachin Singh, IRS Chief Executive Officer

For & on Behalf of BPPI, New Delhi